NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Your 24-25 months is a bit high IMO. I think Control will do slightly better than the ACT IV trial (ITT). Maybe 20-22 months.

Glad to see you estimating down because that would be quite high for control. Let's not forget their are around 30 control patients out of 110 who never even received DCVax treatment - it is thought in most cases NOT to be due to the fact that those control patients never evented - but instead because they became too sick too quickly to receive DCVax.

We'll use your numbers.

Why? Why not use your prediction of 20 to 22? That should show a higher month advantage - not just 3.

Would you please use your low prediction - 20 - since you went with Doc's high prediction - 25? That way we can see what changing the numbers around does to getting OS closer to being stat sig.



If control does 20 months and DCVax does 28 months then, with 233 events what would the p value would be instead of 0.42.

Not even close to stat sig. Not by a mile.

Is it get closer now?

How many events (compared to 1350) do you need then to hit SS?

And I have reason to believe the control arm (as you note above) will perform even better than the ACT IV trial (who were all EGFR+).

Why? Are you suggesting that GBM patients with EGFRv3 expression don't fare as well when compared to other GBM subtypes?

The control arm in the Rindo trial also received keyhole limpet hemocyanin, a known immune adjuvant and protein carrier for tumor antigens. So it's very possible the Rindo control arm would have performed better than the control arm for DCVax, at least for PFS, which did not receive KLH. But perhaps you are thinking of something else.